Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

INVO Fertility (IVF) Current Assets (2016 - 2025)

INVO Fertility has reported Current Assets over the past 16 years, most recently at $1.1 million for Q3 2025.

  • Quarterly Current Assets fell 41.93% to $1.1 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Sep 2025, down 41.93% year-over-year, with the annual reading at $1.3 million for FY2024, 4.65% up from the prior year.
  • Current Assets was $1.1 million for Q3 2025 at INVO Fertility, down from $1.4 million in the prior quarter.
  • Over five years, Current Assets peaked at $9.6 million in Q1 2021 and troughed at $621087.0 in Q4 2022.
  • The 5-year median for Current Assets is $1.8 million (2023), against an average of $2.9 million.
  • Year-over-year, Current Assets surged 1290.45% in 2021 and then tumbled 90.15% in 2022.
  • A 5-year view of Current Assets shows it stood at $6.3 million in 2021, then tumbled by 90.15% to $621087.0 in 2022, then surged by 102.83% to $1.3 million in 2023, then grew by 4.65% to $1.3 million in 2024, then decreased by 13.77% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for IVF's Current Assets are $1.1 million (Q3 2025), $1.4 million (Q2 2025), and $1.6 million (Q1 2025).